These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 20383708

  • 1. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
    Ahn S, Hwang DJ, Barrett CM, Yang J, Duke CB, Miller DD, Dalton JT.
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
    [Abstract] [Full Text] [Related]

  • 2. I-387, a novel antimitotic indole, displays a potent in vitro and in vivo antitumor activity with less neurotoxicity.
    Ahn S, Duke CB, Barrett CM, Hwang DJ, Li CM, Miller DD, Dalton JT.
    Mol Cancer Ther; 2010 Nov; 9(11):2859-68. PubMed ID: 20829196
    [Abstract] [Full Text] [Related]

  • 3. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
    Cai D, Qiu Z, Yao W, Liu Y, Huang H, Liao S, Luo Q, Xie L, Lin Z.
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
    [Abstract] [Full Text] [Related]

  • 4. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity.
    Meng F, Cai X, Duan J, Matteucci MG, Hart CP.
    Cancer Chemother Pharmacol; 2008 May; 61(6):953-63. PubMed ID: 17639393
    [Abstract] [Full Text] [Related]

  • 5. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity.
    Bacher G, Nickel B, Emig P, Vanhoefer U, Seeber S, Shandra A, Klenner T, Beckers T.
    Cancer Res; 2001 Jan 01; 61(1):392-9. PubMed ID: 11196193
    [Abstract] [Full Text] [Related]

  • 6. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
    Yan J, Pang Y, Sheng J, Wang Y, Chen J, Hu J, Huang L, Li X.
    Biochem Pharmacol; 2015 Sep 01; 97(1):51-61. PubMed ID: 26212540
    [Abstract] [Full Text] [Related]

  • 7. Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells.
    Nathwani SM, Butler S, Fayne D, McGovern NN, Sarkadi B, Meegan MJ, Lloyd DG, Campiani G, Lawler M, Williams DC, Zisterer DM.
    Cancer Chemother Pharmacol; 2010 Aug 01; 66(3):585-96. PubMed ID: 20020128
    [Abstract] [Full Text] [Related]

  • 8. Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
    Li CM, Lu Y, Chen J, Costello TA, Narayanan R, Dalton MN, Snyder LM, Ahn S, Li W, Miller DD, Dalton JT.
    Pharm Res; 2012 Nov 01; 29(11):3053-63. PubMed ID: 22760659
    [Abstract] [Full Text] [Related]

  • 9. LG308, a Novel Synthetic Compound with Antimicrotubule Activity in Prostate Cancer Cells, Exerts Effective Antitumor Activity.
    Qin M, Peng S, Liu N, Hu M, He Y, Li G, Chen H, He Y, Chen A, Wang X, Liu M, Chen Y, Yi Z.
    J Pharmacol Exp Ther; 2015 Dec 01; 355(3):473-83. PubMed ID: 26377911
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis and biological evaluation of a series of pyrano chalcone derivatives containing indole moiety as novel anti-tubulin agents.
    Wang G, Li C, He L, Lei K, Wang F, Pu Y, Yang Z, Cao D, Ma L, Chen J, Sang Y, Liang X, Xiang M, Peng A, Wei Y, Chen L.
    Bioorg Med Chem; 2014 Apr 01; 22(7):2060-79. PubMed ID: 24629450
    [Abstract] [Full Text] [Related]

  • 11. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
    Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY.
    Cancer Res; 2004 Jul 01; 64(13):4621-8. PubMed ID: 15231674
    [Abstract] [Full Text] [Related]

  • 12. Antitumor activity of TZT-1027 (Soblidotin).
    Watanabe J, Minami M, Kobayashi M.
    Anticancer Res; 2006 Jul 01; 26(3A):1973-81. PubMed ID: 16827132
    [Abstract] [Full Text] [Related]

  • 13. A potent indole-3-carbinol derived antitumor agent with pleiotropic effects on multiple signaling pathways in prostate cancer cells.
    Weng JR, Tsai CH, Kulp SK, Wang D, Lin CH, Yang HC, Ma Y, Sargeant A, Chiu CF, Tsai MH, Chen CS.
    Cancer Res; 2007 Aug 15; 67(16):7815-24. PubMed ID: 17699787
    [Abstract] [Full Text] [Related]

  • 14. A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
    Liou JP, Hsu KS, Kuo CC, Chang CY, Chang JY.
    J Pharmacol Exp Ther; 2007 Oct 15; 323(1):398-405. PubMed ID: 17660383
    [Abstract] [Full Text] [Related]

  • 15. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
    Arnst KE, Wang Y, Lei ZN, Hwang DJ, Kumar G, Ma D, Parke DN, Chen Q, Yang J, White SW, Seagroves TN, Chen ZS, Miller DD, Li W.
    Mol Pharmacol; 2019 Jul 15; 96(1):73-89. PubMed ID: 31043459
    [Abstract] [Full Text] [Related]

  • 16. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
    Arnst KE, Wang Y, Hwang DJ, Xue Y, Costello T, Hamilton D, Chen Q, Yang J, Park F, Dalton JT, Miller DD, Li W.
    Cancer Res; 2018 Jan 01; 78(1):265-277. PubMed ID: 29180476
    [Abstract] [Full Text] [Related]

  • 17. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
    Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, Yang BB, Ko BC.
    Clin Cancer Res; 2005 Aug 15; 11(16):6002-11. PubMed ID: 16115945
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics, pharmacodynamics and metabolism of a novel anticancer agent for prostate cancer.
    Yang J, Ahn S, Wu Z, Hwang DJ, Miller DD, Dalton JT.
    Int J Oncol; 2012 Jul 15; 41(1):337-44. PubMed ID: 22576690
    [Abstract] [Full Text] [Related]

  • 19. The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity.
    Zhang LH, Wu L, Raymon HK, Chen RS, Corral L, Shirley MA, Narla RK, Gamez J, Muller GW, Stirling DI, Bartlett JB, Schafer PH, Payvandi F.
    Cancer Res; 2006 Jan 15; 66(2):951-9. PubMed ID: 16424030
    [Abstract] [Full Text] [Related]

  • 20. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV.
    Mol Cell Biochem; 2007 Feb 15; 296(1-2):85-95. PubMed ID: 16960658
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.